AstraZeneca Pharma India Receives Final Income Tax Assessment Order for AY 2022-23
AstraZeneca Pharma India received a final income tax assessment order for AY 2022-23 involving ₹11.88 crores in claims related to transfer pricing and corporate tax adjustments. The company plans to appeal before ITAT while acknowledging that overall financial implications remain undetermined at this stage.
*this image is generated using AI for illustrative purposes only.
AstraZeneca Pharma India Limited has informed stock exchanges about receiving a final assessment order from the Income Tax Department for assessment year 2022-23. The pharmaceutical company disclosed this regulatory development on January 16, 2026, pursuant to SEBI listing obligations.
Assessment Order Details
The final assessment order was passed under sections 143(3) read with sections 144C(13) and 144(B) of the Income Tax Act, 1961. This order represents a subsequent development to the draft order that the company had received earlier and disclosed to exchanges on March 19, 2025.
The assessment involves adjustments on legacy transfer pricing and corporate tax issues, highlighting ongoing regulatory scrutiny in the pharmaceutical sector.
Financial Implications
The key financial and procedural details of the assessment are outlined below:
| Parameter: | Details |
|---|---|
| Assessment Year: | 2022-23 |
| Quantum of Claims: | ₹11.88 crores (approx.) |
| Exclusions: | Interest and penalty not included |
| Opposing Party: | Assessment Unit, Income Tax Department |
| Appeal Forum: | Income-tax Appellate Tribunal (ITAT) |
Company's Response Strategy
AstraZeneca Pharma India has indicated its intention to challenge the assessment order through appropriate legal channels. The company plans to file an appeal before the Income-tax Appellate Tribunal (ITAT) to contest the proposed adjustments.
The management has stated that the matter will be suitably challenged in due course, though they acknowledge that the expected overall financial implication cannot be determined at this stage of proceedings.
Regulatory Compliance
The disclosure was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information as required under SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, ensuring transparency with stakeholders regarding material developments.
This development adds to the ongoing transfer pricing disputes that pharmaceutical companies face, particularly regarding legacy issues from previous assessment years.
Historical Stock Returns for AstraZeneca Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.24% | -2.37% | -9.73% | -10.02% | +17.50% | +95.32% |
19
